Creative Biolabs

DGEA Pep-LNP

Datasheet Mdsd
COA

Cat. No.: TDLD-0126-LD81

DGEA Pep-LNP

DGEA Pep-LNP is an advanced peptide-functionalized lipid nanoparticle (LNP) engineered with DGEA peptide for targeted delivery. The DGEA peptide enables specific binding to integrin receptors, facilitating active targeted delivery of therapeutic payloads. Applications include targeted therapeutics development and integrin-mediated biological studies. Please note that this product is intended for research purposes only.

Inquiry
SPECIFIC INQUIRY
Payload:
Modification:
Lipid Formulation:
Dye:
Concentration:
Quantity:
Clear All Inquiry
For Research Use Only. Not for Diagnostic or Treatment Applications.
Payload Type mRNA
Payload Empty; EGFP mRNA; Firefly Luciferase mRNA; mCherry mRNA; GFP mRNA; OVA mRNA; EPO mRNA; Renilla Luciferase mRNA; Gaussia Luciferase mRNA; Beta-galactosidase mRNA; Cre mRNA; mOrange mRNA; tdTomato mRNA; EYFP mRNA; Others
Capping Cap 1
Modification Unmodified; N1-methyl-pseudouridine; 5-methoxyuridine; Other
Module Type Peptide
Targeting Module DGEA Peptide
LNP Type Pep-LNP; Empty LNP; mRNA-LNP
Target Integrin receptors
Lipid Formulation DLin-MC3-DMA; LP-01; ALC-0315; SM102; Other
Dye Unlabeled; DiR; DiD; DiO; DiI; Other
Application Control; Targeted Delivery; Gene Therapy
Format Liquid
Concentration 0.1 mg/mL; 0.2 mg/mL; Other (Please Specify)
Size 65-120 nm
PDI < 0.2
Zeta ± 20.0 mV
Encapsulate Efficiency >90%
Shipping Dry Ice
Storage Store at -80°C

Click the button below to contact us or submit your feedback about this product.

Customer Reviews and Q&As
Related Products
GPLGVRGK Pep-LNP (TDLD-0126-LD96) R6H4 Pep-LNP (TDLD-0825-LD85) cRGD Pep-LNP (TDLD-0126-LD157) Pep42 Pep-LNP (TDLD-0126-LD126) IRQ Pep-LNP (TDLD-0126-LD108) GPC3 CAR mRNA-LNP (TDLD-0825-LD47) RGD Pep-LNP (TDLD-0825-LD79) M2pep Pep-LNP (TDLD-0825-LD76)
Online Inquiry

Customer Review

Creatibe Biolabs' custom LNP was the only solution that successfully delivered our CRISPR-Cas9 payload across the blood-brain barrier with high efficiency and low toxicity.”

Dr. Evelyn Reed

Postdoctoral Researcher, Leading University

Our siRNA candidate was failing due to off-target toxicity, but Creatibe Biolabs' team rapidly redesigned our LNP using their modular platform, rescuing our preclinical program.”

Ben Carter

Project Manager

Achieving cytosolic delivery of our protein degrader with Creatibe Biolabs' exosome platform was the key to unlocking our candidate's full therapeutic potential.”

Dr. Kenji Tanaka

Principal Scientist, Large Pharma Corp

Our oncology drug's efficacy was limited by poor tumor accumulation. Creatibe Biolabs' peptide-conjugated liposomes provided the precise targeting we needed, dramatically increasing the drug's therapeutic index.”

Dr. Clara Schmidt

Senior Scientist, Oncology Innovations Inc.

We required a delivery system that would only release its payload in the tumor's acidic microenvironment. Creatibe Biolabs' pH-responsive liposomes performed flawlessly, minimizing systemic exposure.”

David Chen

Formulation Scientist

Outstanding expertise in antibody engineering.The team's attention to detail and innovative approaches have sianificantly accelerated our development timeline.

Sarah L.

Senior Research Scientist

Contact us for more information Get free consultations